FloraSeq

FloraSeq, LLC operated as a healthcare company concentrating on the human microbiome. The firm's strategy was twofold: to develop and provide therapeutic products aimed at promoting gut health and alleviating gastrointestinal issues, and to supply complementary clinical laboratory services for the diagnosis of infectious diseases and gut dysbiosis.

The company was co-founded by Karen Harrington and Steve Visuri, who also served as CEO. The project team included Andy Greene, a Professor of Biotechnology and Biomedical Engineering at the Medical College of Wisconsin. The company's primary product in development was the FloraSeq FS-0809, a microbiota capsule designed as a therapeutic for Clostridioides difficile (C. diff) infections, which are frequently acquired in hospital settings. This treatment is based on introducing healthy, human-derived bacteria to outcompete the pathogenic bacteria causing the infection.

FloraSeq's business model focused on treating patients with gut dysbiosis by leveraging what was described as a "bugs as drugs" approach. The company secured $50,000 in funding to support its operations. However, reports indicate that the company is no longer in business.

Keywords: FloraSeq, microbiome therapeutics, gut health, gastrointestinal ailments, C. diff infection, microbiota capsules, clinical laboratory services, infectious disease diagnosis, gut dysbiosis, human-derived bacteria, bugs as drugs, Karen Harrington, Steve Visuri, healthcare, biotechnology, medical diagnostics, microbial therapy, hospital-acquired infections, therapeutic products